These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32864509)

  • 1. Update to Drugs, Devices, and the FDA: How Recent Legislative Changes Have Impacted Approval of New Therapies.
    Van Norman GA
    JACC Basic Transl Sci; 2020 Aug; 5(8):831-839. PubMed ID: 32864509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prescription Drug User Fee Act: Much More Than User Fees.
    Mitchell AP; Trivedi NU; Bach PB
    Med Care; 2022 Apr; 60(4):287-293. PubMed ID: 35149663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA efficiency for approval process of COVID-19 therapeutics.
    Cassidy C; Dever D; Stanbery L; Edelman G; Dworkin L; Nemunaitis J
    Infect Agent Cancer; 2020 Dec; 15(1):73. PubMed ID: 33292374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs.
    Van Norman GA
    JACC Basic Transl Sci; 2016 Apr; 1(3):170-179. PubMed ID: 30167510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try".
    Van Norman GA
    JACC Basic Transl Sci; 2018 Apr; 3(2):280-293. PubMed ID: 30062214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prescription Drug User Fee Act of 1992 and the new drug development process.
    Kaitin KI
    Am J Ther; 1997; 4(5-6):167-72. PubMed ID: 10423607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies.
    Van Norman GA
    JACC Basic Transl Sci; 2018 Jun; 3(3):403-414. PubMed ID: 30062226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
    Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
    Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prescription Drug User Fee Act: Cause for Concern?
    Gabay M
    Hosp Pharm; 2018 Apr; 53(2):88-89. PubMed ID: 29581600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI; Manocchia M
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmic Drug Discovery in the United States over the past Two Decades.
    Gu D; Janetos TM
    Ophthalmic Epidemiol; 2021 Feb; 28(1):21-26. PubMed ID: 32597285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.
    Berndt ER; Gottschalk AH; Philipson TJ; Strobeck MW
    Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA censoring of manufacturers' postmarketing commitments in HIV/AIDS drug approval letters.
    Unalp A; Shafer C; Tonascia S; Meinert C
    Am J Ther; 2000 Aug; 7(4):257-63. PubMed ID: 11486160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approval times for new drugs: does the source of funding for FDA staff matter?
    Carpenter D; Chernew M; Smith DG; Fendrick AM
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-618-24. PubMed ID: 15506165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.